Genocea Biosciences (GNCA) has a profit margin of -14542.59%, below the Healthcare sector average of 14.34%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2022
Trailing 12 months ending Mar 2022
The latest profit margin for GNCA is -14542.59% as of March 2022. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Genocea Biosciences's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, GNCA currently prints -14542.59% for profit margin, while the sector average sits near 14.34%. That is roughly 101479.0% below the sector mean. Large gaps often invite a closer look at Genocea Biosciences's growth, margins, and balance sheet.
Profit Margin shows how effectively Genocea Biosciences converts resources into returns. At -14542.59%, GNCA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GNCA's profit margin (-14542.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Genocea Biosciences's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.